CTRE vs SBRA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CTRE is the larger of the two ($9.85B market cap): the incumbent the market prices for continued execution (20.35x forward earnings, beta 0.79). SBRA is the smaller challenger ($5.56B), actually pricier on forward earnings (29.26x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CTRE vs SBRA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCTRESBRAWhat it tells you
Market cap$9.85B$5.56BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E20.3529.26Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E24.0378.56Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.790.64Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range39% of range70% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.851.96How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: CTRE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CTRE and SBRA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CTRE and SBRA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CTRE and SBRA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does CareTrust REIT (CTRE) do?

CareTrust REIT owns healthcare real estate and does not operate any of it. The portfolio is mostly skilled nursing facilities, with a growing share of senior housing, assisted living and multi-service campuses, spread across roughly 30 US states and, since the 2025 acquisition of UK-listed Care REIT plc, the United Kingdom. Properties are leased to regional and national operators under triple-net structures, meaning the tenant pays taxes, insurance and maintenance and CareTrust collects contractual rent with annual escalators. The company was spun off from The Ensign Group in 2014, which is why Ensign remains its largest tenant, and it has since diversified into a roster where the top ten operators account for roughly 69% of rent. Alongside owned real estate it runs a mortgage and mezzanine loan book, which supplies a pipeline into future acquisitions.

Full CTRE guide

What does Sabra Health Care REIT (SBRA) do?

Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals, spread across the United States and Canada. Its portfolio mixes triple-net leases (where operators pay Sabra fixed rent) with managed senior housing under RIDEA-style structures that give Sabra direct exposure to the operating income of those communities, so a chunk of its results moves with occupancy and rate trends in senior living.

Full SBRA guide

CTRE vs SBRA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CTRE drivers: Acquisitions at a wide spread over cost of capital; A balance sheet with almost no leverage.
  • SBRA drivers: Senior housing operating recovery; Investment pipeline and acquisitions.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. For SBRA, sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection.

CTRE or SBRA: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CTRE if you believe its drivers more; SBRA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CTRE and SBRA guides.

CTRE vs SBRA: the full fundamentals

CTRE. Trailing net income of ~$356 million (~$1.60 per share, ~23x on a P/E basis) understates the cash the business generates, because REIT accounting charges large non-cash depreciation against buildings that are not actually losing value, which is why guidance and the dividend are both framed against normalized FFO and FAD. At ~18x the raised FFO guidance, the multiple has compressed from ~19x in August as the shares slid, leaving it above most skilled nursing landlords and below the diversified large-cap healthcare REITs. Analysts' mean target is about $43.79 across 14 analysts, and third-quarter results are expected around November 9, 2026, with consensus EPS near $0.43 on ~$158 million of revenue.

SBRA. At $19.41 on October 16, 2026, the shares trade at roughly 12 times annualized second-quarter normalized AFFO and about 1.8 times book value; GAAP P/E figures (about 78 trailing) are distorted by depreciation and the second-quarter reserve and say little about a REIT. The $0.30 quarterly dividend is about 75% of normalized AFFO, leaving some cushion. Third-quarter results on November 4, 2026 will show whether same-store senior housing NOI growth stays in the low-to-mid teens and how quickly the new acquisitions add to AFFO.

Headline figures (approximate, October 2026): CTRE shows revenue (ttm) ~$571 million, with Q2 2026 at ~$161 million versus ~$113 million a year earlier (~+43%), normalized ffo per share (q2 2026) ~$0.51, up ~19% year over year, fy2026 normalized ffo per share guidance ~$2.06 to $2.09, raised in October from $2.03 to $2.06, net income (ttm) ~$356 million, ~$1.60 per share; SBRA shows market cap ~$5.0B, revenue (ttm) ~$864M (+25% y/y in Q2 2026), normalized affo/share (q2 2026) $0.40 (+5% y/y), normalized ffo/share (q2 2026) $0.38.

The bottom line: CTRE vs SBRA

CTRE and SBRA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CTRE and SBRA exposure against your real portfolio. It is not an investment adviser.

Wondering how CTRE or SBRA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about CareTrust REIT

Ask Walnut's AI anything about CTRE and see how it fits what you own.

FAQ

What is the difference between CTRE and SBRA?

+

CareTrust REIT owns healthcare real estate and does not operate any of it. Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals, spread across the United States and Canada. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CTRE or SBRA the better stock?

+

Neither is universally better. CTRE is the larger incumbent; SBRA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CTRE or SBRA?

+

On forward P/E (as of November 2026), CTRE trades at 20.35x and SBRA at 29.26x, so CTRE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CTRE and SBRA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CTRE vs SBRA?

+

CTRE: Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Reimbursement policy sits underneath everything, since US operators are paid mostly by Medicare and Medicaid, and the 2025 federal law steps the state provider tax cap down from 6% to 3.5% by fiscal 2032 in Medicaid expansion states while individual states debate their own rate cuts. The growth model itself is a dependency: mid-teens FFO per share growth requires continuously issuing equity and finding deals at attractive yields, and if either the equity window closes or cap rates compress, the growth rate resets to escalators alone. The UK expansion raises the stakes on that model: an operating portfolio carries occupancy and cost risk that a triple-net lease passes to the tenant, the second LNT tranche depends on construction and regulatory approvals, and rent is earned in pounds while results are reported in dollars. Interest rates cut both ways, raising the cost of the debt CareTrust has not yet drawn and setting the yield investors demand on the stock. Sentiment has cooled too: the stock fell about 16% over three months to October 16, 2026, and JPMorgan initiated coverage at Neutral with a $41 target that day. SBRA: Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The re-tenanting of properties (such as the Avamere-to-Cascadia transition) carries execution risk during handover. As a REIT it is sensitive to interest rates, which affect both its borrowing costs and how income investors value its yield. Leverage remains meaningful for a healthcare landlord, and the dividend, while covered by cash flow today, depends on continued occupancy recovery. Competition from far larger peers for acquisitions can compress the yields Sabra earns on new deals. The second-quarter 2026 provision of $102.4 million for loan losses, tied to the discounted payoff of a mortgage loan, is a reminder that Sabra's lending and leasing exposure to operators can produce sizable write-downs. Reliance on forward equity sales to fund acquisitions also dilutes existing holders, and GAAP payout ratios look stretched (the trailing dividend is several times GAAP earnings) even though the normalized AFFO payout is about 75%.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CTRE or SBRA; figures are approximate and dated (as of November 2026). Verify current data before investing.